AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 165 filers reported holding AKERO THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.70 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,287,164 | +99.1% | 322,008 | +83.8% | 0.13% | +80.0% |
| Q2 2023 | $8,180,088 | +258.3% | 175,200 | +193.6% | 0.07% | +218.2% |
| Q1 2023 | $2,283,280 | -57.6% | 59,678 | -39.2% | 0.02% | -51.1% |
| Q4 2022 | $5,378,949 | +1675.2% | 98,156 | +1002.9% | 0.04% | +1400.0% |
| Q3 2022 | $303,000 | +34.7% | 8,900 | -62.8% | 0.00% | +50.0% |
| Q2 2022 | $225,000 | – | 23,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |